NCT06542770

Brief Summary

Cryptogenic stroke (CS) causes about 30% of admissions to a stroke unit. Silent paroxysmal atrial fibrillation (PAF) is believed to be the underlying cause of a significant proportion of patients. The use of implantable cardiac monitors (ICM) early after the CS has demonstrated benefits in the diagnostic yield, but the indication for ICM in the current guidelines remains unclear. Atrial contraction strain (ACS) evaluated by cardiac ultrasound could be of help to select the patients more prone to suffer from silent PAF. The purpose of this investigation is to conduct a randomized prospective unicentric study to evaluate the usefulness of ICM for early detection of silent PAF episodes in patients with CS. Clinical and ultrasound predictors of PAF occurrence (ACS) will be studied in order to define patients needing a closer follow-up.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
3.6 years until next milestone

First Submitted

Initial submission to the registry

July 21, 2024

Completed
17 days until next milestone

First Posted

Study publicly available on registry

August 7, 2024

Completed
25 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

August 7, 2024

Status Verified

August 1, 2024

Enrollment Period

3.7 years

First QC Date

July 21, 2024

Last Update Submit

August 2, 2024

Conditions

Keywords

Atrial strain. Implantable cardiac monitor

Outcome Measures

Primary Outcomes (1)

  • Detection atrial fibrilation at follow-up

    defined by the presence of a confirmatory 12-leads ECG, or a registration lasting more than 30 seconds in, either the 72h-Holter-Monitoring, or in the ICM recording. In case of AF detection OAC was initiated immediately.

    Up to 2 years follow-up (ICM and standard care practice)

Secondary Outcomes (5)

  • LA indexed volume

    Before Day 3 since the Criptogenic Stroke

  • Maximum Systolic Global Longitudinal Strain (PALs)

    Before Day 3 since the Criptogenic Stroke

  • Atrial Contraction Strain (PACs)

    Before Day 3 since the Criptogenic Stroke

  • Atrial Ejection Fraction

    Before Day 3 since the Criptogenic Stroke

  • stroke recurrences

    Up to 2 years follow-up (ICM and standard care practice)

Study Arms (4)

Atrial cardiomyopathy by echocardiogram intervention

EXPERIMENTAL

Presence of Atrial cardiomyopathy is defined by echocardiogram if ANY of the following is present: 1. LA dilatation: indexed volumen \>32 ml/m2 2. PALS (Peak atrial longitudinal strain) \<21% 3. PACS ( Peak atrial contraction strain ) \<13% 4. Atrial ejection fraction \<55%

Device: Early implant of cardiac monitor

Atrial cardiomyopathy by echocardiogram standard practice

NO INTERVENTION

Presence of Atrial cardiomyopathy is defined by echocardiogram if ANY of the following is present: 1. LA dilatation: indexed volumen \>32 ml/m2 2. PALS (Peak atrial longitudinal strain) \<21% 3. PACS ( Peak atrial contraction strain ) \<13% 4. Atrial ejection fraction \<55%

Non atrial cardiomyopathy by echocardiogram intervention

EXPERIMENTAL

Absence of atrial cardiomyopathy is defined by echocardiogram if none of the characteristics bellow were accomplished. 1. LA dilatation: indexed volumen \>32 ml/m2 2. PALS (Peak atrial longitudinal strain) \<21% 3. PACS ( Peak atrial contraction strain ) \<13% 4. Atrial ejection fraction \<55%

Device: Early implant of cardiac monitor

Non atrial cardiomyopathy by echocardiogram standard practice

NO INTERVENTION

Absence of atrial cardiomyopathy defined by echocardiogram if none of the characteristics bellow were accomplished. 1. LA dilatation: indexed volumen \>32 ml/m2 2. PALS (Peak atrial longitudinal strain) \<21% 3. PACS ( Peak atrial contraction strain ) \<13% 4. Atrial ejection fraction \<55%

Interventions

ICM implant 3-4 days after the stroke and prior to discharge. All devices (Abbott Confirm or Jot) were implanted subcutaneously under local anaesthesia in the left chest region and programmed with an specific algorithm for AF detection set at 30 seconds for detection. All patients were included in remote monitoring system (Merlin), which was programmed to send alerts in case of registering episodes qualifying for AF detection, and a monthly routine registration. All ICM recordings were reviewed by a specialized cardiologist.

Atrial cardiomyopathy by echocardiogram interventionNon atrial cardiomyopathy by echocardiogram intervention

Eligibility Criteria

Age50 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Acute ischemic stroke or transient ischemic attack (TIA) from January 2022 to July 2023
  • Age between 50 and 89 years;
  • Undetermined origin at hospital admission according to the SSS-TOAST criteria (2):
  • Absence of major structural heart disease by cardiac ultrasound (normal global and segmental left ventricle contraction, absence of valvular/rheumatic disease, absence of intracardiac shunts)
  • Absence of AF during 48h ECG-monitoring
  • Absence of major anomalies in the supra-aortic trunks ultrasound.

You may not qualify if:

  • Patients with a history of hemorrhagic stroke;
  • Presence with prior atrial fibrillation or atrial flutter;
  • Permanent contraindication or indication for OAC for other reasons;
  • Recent (\<1 month) major surgery or cardiac events;
  • Presence of severe cardiac abnormalities;
  • Patients with life expectancy \<1 year or severe stroke (modified Rankin Scale \> 4).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital del Mar

Barcelona, 08003, Spain

RECRUITING

Related Publications (15)

  • Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? Neuroepidemiology. 2013;40(4):227-39. doi: 10.1159/000343667. Epub 2013 Jan 24.

    PMID: 23364221BACKGROUND
  • Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2015 Apr;14(4):377-87. doi: 10.1016/S1474-4422(15)70027-X. Epub 2015 Mar 4.

    PMID: 25748102BACKGROUND
  • Rubiera M, Aires A, Antonenko K, Lemeret S, Nolte CH, Putaala J, Schnabel RB, Tuladhar AM, Werring DJ, Zeraatkar D, Paciaroni M. European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin. Eur Stroke J. 2022 Sep;7(3):VI. doi: 10.1177/23969873221099478. Epub 2022 Jun 3.

    PMID: 36082257BACKGROUND
  • Cuadrado-Godia E, Benito B, Ois A, Valles E, Rodriguez-Campello A, Giralt-Steinhauer E, Cabrera S, Alcalde O, Jimenez-Lopez J, Jimenez-Conde J, Marti-Almor J, Roquer J. Ultra-early continuous cardiac monitoring improves atrial fibrillation detection and prognosis of patients with cryptogenic stroke. Eur J Neurol. 2020 Feb;27(2):244-250. doi: 10.1111/ene.14061. Epub 2019 Sep 18.

    PMID: 31424609BACKGROUND
  • Klijn CJ, Paciaroni M, Berge E, Korompoki E, Korv J, Lal A, Putaala J, Werring DJ. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J. 2019 Sep;4(3):198-223. doi: 10.1177/2396987319841187. Epub 2019 Apr 9.

    PMID: 31984228BACKGROUND
  • Pagola J, Juega J, Francisco-Pascual J, Bustamante A, Penalba A, Pala E, Rodriguez M, De Lera-Alfonso M, Arenillas JF, Cabezas JA, Moniche F, de Torres R, Montaner J, Gonzalez-Alujas T, Alvarez-Sabin J, Molina CA; Crypto-AF study group. Predicting Atrial Fibrillation with High Risk of Embolization with Atrial Strain and NT-proBNP. Transl Stroke Res. 2021 Oct;12(5):735-741. doi: 10.1007/s12975-020-00873-2. Epub 2020 Nov 13.

    PMID: 33184686BACKGROUND
  • Albers GW, Bernstein RA, Brachmann J, Camm J, Easton JD, Fromm P, Goto S, Granger CB, Hohnloser SH, Hylek E, Jaffer AK, Krieger DW, Passman R, Pines JM, Reed SD, Rothwell PM, Kowey PR. Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. J Am Heart Assoc. 2016 Mar 15;5(3):e002944. doi: 10.1161/JAHA.115.002944. No abstract available.

    PMID: 27068633BACKGROUND
  • Rubio Campal JM, Garcia Torres MA, Sanchez Borque P, Navas Vinagre I, Zamarbide Capdepon I, Miracle Blanco A, Bravo Calero L, Saez Pinel R, Tunon Fernandez J, Serratosa Fernandez JM. Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (from the DAF-ESUS registry). Am J Cardiol. 2020 Feb 1;125(3):409-414. doi: 10.1016/j.amjcard.2019.10.050. Epub 2019 Nov 6.

    PMID: 31780074BACKGROUND
  • Marks D, Ho R, Then R, Weinstock JL, Teklemariam E, Kakadia B, Collins J, Andriulli J, Hunter K, Ortman M, Russo AM. Real-world experience with implantable loop recorder monitoring to detect subclinical atrial fibrillation in patients with cryptogenic stroke: The value of p wave dispersion in predicting arrhythmia occurrence. Int J Cardiol. 2021 Mar 15;327:86-92. doi: 10.1016/j.ijcard.2020.11.019. Epub 2020 Nov 10.

    PMID: 33186666BACKGROUND
  • Chorin E, Peterson C, Kogan E, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Schole M, Duraiswami H, Spinelli M, Park D, Chinitz L, Jankelson L. Comparison of the Effect of Atrial Fibrillation Detection Algorithms in Patients With Cryptogenic Stroke Using Implantable Loop Recorders. Am J Cardiol. 2020 Aug 15;129:25-29. doi: 10.1016/j.amjcard.2020.05.027. Epub 2020 May 23.

    PMID: 32600783BACKGROUND
  • Magnusson P, Lyren A, Mattsson G. Diagnostic yield of chest and thumb ECG after cryptogenic stroke, Transient ECG Assessment in Stroke Evaluation (TEASE): an observational trial. BMJ Open. 2020 Sep 24;10(9):e037573. doi: 10.1136/bmjopen-2020-037573.

    PMID: 32973062BACKGROUND
  • Lumikari TJ, Putaala J, Kerola A, Sibolt G, Pirinen J, Pakarinen S, Lehto M, Nieminen T. Continuous 4-week ECG monitoring with adhesive electrodes reveals AF in patients with recent embolic stroke of undetermined source. Ann Noninvasive Electrocardiol. 2019 Sep;24(5):e12649. doi: 10.1111/anec.12649. Epub 2019 May 2.

    PMID: 31045315BACKGROUND
  • Kalani R, Bernstein R, Passman R, Curran Y, Ruff I, Prabhakaran S. Factual Inaccuracies Contained in the Article Entitled "Low Yield of Mobile Cardiac Outpatient Telemetry after Cryptogenic Stroke in Patients with Extensive Cardiac Imaging". J Stroke Cerebrovasc Dis. 2017 Dec;26(12):3035. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.018. Epub 2017 Oct 18. No abstract available.

    PMID: 29054732BACKGROUND
  • Ziegler PD, Rogers JD, Ferreira SW, Nichols AJ, Richards M, Koehler JL, Sarkar S. Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population. Int J Cardiol. 2017 Oct 1;244:175-179. doi: 10.1016/j.ijcard.2017.06.039. Epub 2017 Jun 10.

    PMID: 28624331BACKGROUND
  • Ziegler PD, Rogers JD, Ferreira SW, Nichols AJ, Sarkar S, Koehler JL, Warman EN, Richards M. Real-World Experience with Insertable Cardiac Monitors to Find Atrial Fibrillation in Cryptogenic Stroke. Cerebrovasc Dis. 2015;40(3-4):175-81. doi: 10.1159/000439063. Epub 2015 Aug 28.

    PMID: 26314298BACKGROUND

MeSH Terms

Conditions

Atrial FibrillationArrhythmias, CardiacIschemic Stroke

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsStrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular Diseases

Study Officials

  • Ermengol Valles Gras, PhD

    Hospital del Mar

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ermengol Valles Gras, PhD

CONTACT

Ana Beatriz Garcia Duran, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: Randomized prospective parallel study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of arrhythmias

Study Record Dates

First Submitted

July 21, 2024

First Posted

August 7, 2024

Study Start

January 1, 2021

Primary Completion

September 1, 2024

Study Completion

December 1, 2024

Last Updated

August 7, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will share

All data from this study, including pseudoanonimized data from ultrasound exams and ECG signals from ICM will be available.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
After the publication and during 10 years
Access Criteria
Upon reasonable request

Locations